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leads to efficient activation of virus-specific human
memory t cells
Wei Ye
1,2,3, Yun Xing
3,4, Christopher Paustian
5, Rieneke van de Ven
5, Tarsem Moudgil
5, Traci L Hilton
6,
Bernard A Fox
5,7, Walter J Urba
8, Wei Zhao
1,2* and Hong-Ming Hu
1,2,3*
Abstract
Background: Autophagy regulates innate and adaptive immune responses to pathogens and tumors. We have
reported that autophagosomes derived from tumor cells after proteasome inhibition, DRibbles (Defective ribosomal
products in blebs), were excellent sources of antigens for efficient cross priming of tumor-specific CD8
+ Tc e l l s ,w h i c h
mediated regression of established tumors in mice. But the activity of DRibbles in human has not been reported.
Methods: DRibbles or cell lysates derived from HEK293T or UbiLT3 cell lines expressing cytomegalovirus (CMV) pp65
protein or transfected with a plasmid encoding dominant HLA-A2 restricted CMV, Epstein-Barr virus (EBV), and
Influenza (Flu) epitopes (CEF) were loaded onto human monocytes or PBMCs and the response of human CMV
pp65 or CEF antigen-specific CD4
+ and CD8
+ memory T cells was detected by intracellular staining. The effect of
cytokines (GM-CSF, IL-4, IL-12, TNF-α,I F N - α and IFN-γ) TLR agonists (Lipopolysaccharide, Polyinosinic-polycytidylic
acid (poly(I:C), M52-CpG, R848, TLR2 ligand) and CD40 ligand on the cross-presentation of antigens contained in
DRibbles or cell lysates was explored.
Results: In this study we showed that purified monocytes, or human PBMCs, loaded with DRibbles isolated from
cells expressing CMV or CEF epitopes, could activate CMV- or CEF-specific memory T cells. DRibbles were significantly
more efficient at stimulating CD8
+ memory T cells compared to cell lysates expressing the same antigenic epitopes.
We optimized the conditions for T-cell activation and IFN-γ production following direct loading of DRibbles onto
PBMCs. We found that the addition of Poly(I:C), CD40 ligand, and GM-CSF to the PBMCs together with DRibbles
significantly increased the level of CD8
+ T cell responses.
Conclusions: DRibbles containing specific viral antigens are an efficient ex vivo activator of human antigen-specific
memory T cells specific for those antigens. This function could be enhanced by combining with Poly(I:C), CD40 ligand,
and GM-CSF. This study provides proof-of-concept for applying this strategy to activate memory T cells against other
antigens, including tumor-specific T cells ex vivo for immunological monitoring and adoptive immunotherapy, and
in vivo as vaccines for patients with cancer.
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Cytotoxic T lymphocytes (CTLs) play critical roles in the
clearance of tumor cells and cells infected with intracel-
lular pathogens. Efficient activation of polyvalent and
multi-functional antigen-specific CD8
+ T cells is the Holy
Grail for the development of therapeutic vaccines for
cancer and chronic infections [1,2]. For tumor-associated
antigens (TAAs), the development of a CTL response
relies on antigen cross-presentation, a process during
which the transformed or over-expressed antigens expressed
by tumor cells are captured, processed and cross-presented
to CD8
+ T cells by professional antigen-presenting cells
(pAPCs), such as dendritic cells (DCs) [3,4]. The assump-
tion is that most tumor antigens are passively released
from healthy or dying tumor cells as intact soluble anti-
gens, peptide fragments complexed with heat shock
protein chaperones, or packaged in secretory vesicles in
the form of microparticles or exosome nanoparticles. Our
previous studies with mouse tumor models identified
autophagy as one of the critical pathways regulating
antigen packaging and transfer from tumor cells to
dendritic cells for cross-presentation to T cells [5,6].
Autophagy is a homeostatic process that involves
the sequestration of cytoplasmic components in double-
membrane autophagosomes, which subsequently fuse with
lysosomes to form autolysosomes, where their cargoes
are enzymatically degraded and recycled [7,8]. We have
shown that autophagy in tumor cells also plays a critical
role in cross-presentation of tumor antigens and identified
autophagosomes as antigen carriers for efficient cross-
presentation [9,10]. Based on these findings, we developed
a novel vaccine strategy to produce DRibbles whose major
structure and functional constituents are autophagosomes.
Tumor-derived vesicles produced under normal growth
conditions contain few ubiquitinated proteins, whereas
DRibbles produced from tumor cells treated with inhib-
itors of proteasomes and lysosomes contain a broad
spectrum of cellular antigens, including long-lived proteins,
ubiquitinated short-lived proteins (SLiPs), and defective
ribosomal products (DRiPs) [9]. DRibbles efficiently cross-
prime antigen-specific naïve CD8
+ and CD4
+ Tcells in vitro
and in vivo; and immunotherapy with DRibbles isolated
from a variety of murine tumor cell lines is protective or
therapeutic in mice bearing established melanomas, lung
carcinomas, breast carcinomas, and sarcomas [10,11].
A pilot Phase I clinical trial using DRibbles derived
from autologous tumor cells to vaccinate patients with
non-small cell lung cancer has been completed and a
randomized multi-center Phase II clinical trial using
Allogeneic DRibbles has been initiated (Sanborn, manu-
script in preparation). The vaccine employed in the phase
II study contains at least 25 putative cancer antigens,
including 9 cancer antigens that were “prioritized” by
an NCI panel, as well as damage-associated molecular
pattern molecules (DAMPs) (Hilton, manuscript in prep-
aration; van de Ven, manuscript in preparation).
Here we report results using DRibbles to activate
antigen-specific T cells from humans and to serve as a
source of TAA for the immunological monitoring of
tumor antigen-specific Tcell responses for patients under-
going vaccine trials. Cytomegalovirus (CMV), a ubiquitous
herpes virus that infects 50-90% of humans persists in
myeloid cells under the control of specific T cells. CTLs
play a central role in suppressing CMV reactivation and
disease. A relatively high frequency of CMV-specific
memory T cells can be found in CMV serum positive
donors. The dominant CTL response is directed against
the pp65 protein [12]. We devised an ex vivo cross-
presentation assay model system, in which DRibbles were
made from the pp65-expressing HEK293T embryonic
kidney cell line or the non-small cell lung cancer
(NSCLC) cell line UbiLT3 and used to stimulate
PBMCs isolated from CMV serum positive donors.
In this study, we examined whether pp65 DRibbles
derived from either HEK293T or UbiLT3 could activate
human pp65-specific memory CD8
+ T cells and CD4
+
T cells ex vivo by directly adding DRibbles to PBMCs
in culture. Next, we determined the optimal duration
for antigen-presenting cells to acquire, process, and
cross-present antigens in DRibbles to antigen-specific
T cells in PBMCs. Moreover, we tested whether the
cross-presentation of DRibbles by human PMBCs could
be enhanced by adding “DC licensing factors” such as
cytokines and TLR agonists in culture together with
DRibbles [13].
Materials and methods
Human blood donors and preparation of PBMCs
Leukapheresis products were obtained from healthy vol-
unteers. Written informed consent was obtained from all
donors in accordance with the Declaration of Helsinki.
Leukapheresis products were cryopreserved in liquid ni-
trogen. PBMCs were isolated using the density gradient
separation method according to the manufactory’sp r o t o -
col. PBMCs from one of the healthy donors were sepa-
rated into monocytes and lymphocytes by Elutra apheresis
according to the density before cryopreservation. All stud-
ies were approved by the institutional review board (IRB)
of Providence Portland Medical Center.
Tumor cell lines and generation of cell lines expressing
the dominant antigen pp65 of CMV or CEF composite
epitopes
HEK 293 T cells were maintained in Dulbecco’s modified
Eagle’s medium (Lonza, 12-604 F) supplemented with
2 mmol/L L-glutamine, 100 units/ml penicillin and
100 ug/ml streptomycin (Invitrogen, 10378), 1 mmol/L
sodium pyruvate (Lonza, 13-115E), and 10% fetal bovine
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was provided by Dr. Traci Hilton (UbiVac, Portland, OR)
and maintained in complete medium containing RPMI
1640 (Lonza, 12-702Q), 10% FBS, 2 mmol/L L-glutamine,
100 units/ml penicillin and 100 ug/ml streptomycin and
1 mmol/L sodium pyruvate. The pp65 coding sequence
was amplified by PCR from CMV genomic DNA. The
HPV E6 E7 coding sequences were obtained from an
expression vector (kindly provided by Dr. T. C. Wu at
John Hopkins University). The CEF coding sequence was
provided by Dr. John R. Webb. All coding sequences were
cloned into the p6A-O”PB-IPWS transposon vector. The
UbiLT3 pp65 and UbiLT3 GFP control cell line were
generated by transfection of UbiLT3 with pp65 plasmid
vector or control vector encoding GFP protein and two
weeks selection with 2 μg/ml puromycin (Invivogen,
ant-pr-1). Expression of pp65 and GFP was confirmed by
western blot analysis or GFP fluorescence. These cell
populations were used to prepare pp65 DRibbles or
control GFP DRibbles. In some experiments, DRibbles
were generated from HEK293T cells that were transi-
ently transfected with either a CMV pp65 plasmid, a
plasmid encoding dominant HLA-A2 restricted CMV,
EBV, and Flu epitopes (CEF) or a plasmid encoding
HPV E6E7 (as a negative control).
Preparation of DRibbles and cell lysate
Autophagosome-enriched DRibbles were prepared as
described previously [9]. Briefly, cells were treated with
Bortezomib (200 nmol/L, Millennium) and ammonium
chloride (10 ~20 mmol/L, Sigma Aldrich, A9434) for
24 to 48 hours, cells and cellular debris were pelleted
by centrifugation at 300 × g for 7 minutes. DRibbles were
dislodged from cells or clumps of cell debris by rigor-
ous pipetting. The suspension was then centrifuged at
7500× g to pellet the DRibbles and discard supernatant
containing nanovesicles and exosomes. Total cell lysates
were produced by three freeze thaw cycles: freezing in a
dry-ice enthanol bath followed by thawing in a 37°C water
bath. The total amount of protein in DRibbles and lysates
was quantified using a BCA protein assay Kit with the
assay performed according to the manufacturer’s protocol
(Thermo scientific, 23228).
Resting of PBMCs and determine the optimal condition
for DRibbles stimulation of memory T cells ex vivo
For experiments with monocytes and lymphocytes iso-
lated by leukapheresis, monocytes were first thawed,
rested in complete medium containing RPMI 1640, 10%
FBS, 2 mmol/L L-glutamine, 100units/ml penicillin, 100ug/
ml streptomycin and 1 mmol/L sodium pyruvate (RP10)
for 12 hours and seeded into a 96-well round-bottomed
plate at 1×10
5 cells per well. DRibbles were added to
specified wells at indicated concentration and lymphocytes
were thawed and promptly added at 5×10
5 cells per well.
After 12 h stimulation, brefeldin A (10ug/ml, sigma-
aldrich, B7651) was added to the culture for another
6 hours before they were harvested and stained for flow
cytometric analysis.
Frozen PBMCs were thawed and rested in RP10 med-
ium or the medium containing complete medium and
X-VIVO™ 15 (Lonza, 04-418Q) at the ratio of 1:1
(RX15) for 6~ 12 hours. Next, rested cells were seeded
into a 96-well round-bottomed plate at 0.5~1 millions
cells per well and DRibbles, cell lysate or protein were
added at indicated amount. After 12 h of incubation
with DRibbles, brefeldin A (10 ug/ml) was added to the
culture and kept in culture for another 12 hours.
To identify the optimal culture condition for DRibbles-
induced T-cell activation, rested PBMCs were stimulated
by DRibbles in the presence of different DC licensing
factors. These factors included recombinant GM-CSF
(40 ng/ml, immunex), IL-4 (10 ng/ml, peprotech, 200-
04) and IFN-α-2b (1000 U/ml, intron A). Some factors
were added at the same time with antigens including
Lipopolysaccharide (100 ng/ml, immunechem), Poly(I:C)
(25 ug/ml, invivogen, tlrl-piclv), M52-CpG (30 ug/ml,
Sigma), R848 (10 ug/ml, invivogen, tlrl-r848), TLR2 ligand
(300 ng/ml, invivogen, tlrl-pms), CD40 ligand (1 ug/ml,
NIH repository, D759060X), IL-1α(300 ng/ml, NIH re-
pository, Zlva0903), TNF-α (1000 U/ml, Cetus, 94608),
and IFN−γ (100 ng/ml, peprotech, 30002).
Antibodies and western blot analysis
Cell lysates or DRibbles were mixed with 4× NuPAGE
LDS sample buffer. Samples were sonicated and boiled
in 85°C bath for 5 minutes. Samples (10 ug protein in
10ul for each) were resolved by 4% to 20% SDS-PAGE
and transferred to PVDF membranes. Memberanes were
blocked 1 h in PBS-Tween 0.1% containing 5% skim milk
powder and incubated overnight with anti-ubiquitin
(1:2,000, 5379, Sigma) and anti-CMV pp65 (1:1,000,
52401, Santa cruz) at 4°C overnight. Next day membranes
were incubated with HRP-labeled goat-anti-mouse (1:5,000,
31430, Thermo) and goat-anti-rabbit (1:20,000, 31460,
Thermo) secondary antibodies for 1 h and developed
with chemiluminescent reagents (1705070, Bio-Rad).
Analysis of antigen-specific T cells by intracellular IFN-γ
staining and flow cytometry analysis
After stimulation, PBMCs were collected into FACS tubes
and stained with live/dead fixable dead cell staining (Invi-
trogen, L34957) and stained with antibodies against CD3
(peridinin-chlorophyll proteins, Invitrogen, MHCD0331),
CD4 (Alexa Fluor® 488, Invitrogen, MHCD0420), CD8
(Phycoerythrin, Invitrogen, MHCD0804), and IFN-γ (APC,
Invitrogen, MHCIFG05) and analyzed by a custom-build
LSRII flow cytometer (BD bioscience). Data were collected
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Flowjo software.
Statistical analysis
Non-paired or paired t test were performed using Prism
(GraphPad Software). P<0.05 with two tails represented
difference was statistically significant.
Results
Optimization of cross-presentation and intracellular IFN-γ
staining assay for the DRibble-induced human T-cell
responses
We previously reported that tumor-derived DRibbles
when pulsed onto bone marrow-derived DC were highly
efficient carriers of antigen for cross-presentation to
naïve CD8
+ T cells in mice [9]. To investigate whether
DRibbles were also efficient activators of antigen-specific
T cells in humans, elutriated monocytes were used as
antigen-presenting cells and exposed to DRibbles made
from cells expressing viral antigens. Matched Lympho-
cytes that were autologous to the elutriated monocytes
and with pre-existing memory T cells specific for viral
antigens were used as the responder cells. DRibbles were
prepared from HEK293T cells that had been transiently
transfected to express the major T-cell epitopes of CMV,
EBV, and influenza virus (termed as CEF) or E6E7 fu-
sion proteins of HPV as the negative control (the donor
was HPV seronegative) [14]. To measure antigen cross-
presentation, we used the intracellular staining (ICS) assay
and flow cytometric analysis to determine the frequency
of antigen-specific T cells by measuring the production of
IFN-γ. Initial experiments sought to determine the condi-
tions for the processing and presentation of DRibbles that
achieved optimal activation of antigen-specific T-cell
responses. HEK 293 T CEF DRibbles were loaded onto
monocytes for 6 hours, after which T cells were added
into the culture. Brefeldin A was added at different time
points after T-cell addition to determine the duration
of T-cell stimulation required for optimal production
and retention of intracellular IFN-γ. Subsequently, all
cells were harvested at the same time and the ICS was
performed by flow cytometry to calculate the percentage
of IFN-γ
+ T cells. As the culture period without brefeldin
A was extended from 2 hours to 10 hours both the
CD8
+ and CD4
+ T-cell responses increased with a plat-
eau between 10 hours to 16 hours (Figure 1A,B). This
was followed by a significant decline at 24 h.
Next, we determined the optimal timing for the addition
of brefeldin A after direct loading of DRibbles onto PBMC
without monocyte isolation and the preloading of DRib-
bles specified above. Analysis of intracellular IFN-γ stain-
ing revealed that the highest T-cell responses were
detected when brefeldin A was added to culture 12 hours
after stimulation (Figure 1C,D). Collectively, these data
show that when cryopreserved PBMC are assayed, it
takes about 12 hours for DRibbles to be cross-presented
and to activate T cells before adding brefeldin A and
assaying IFN-γ.
Human monocytes or PBMCs “loaded” with DRibbles
efficiently stimulate memory CD8
+ Tc e l l sa n dC D 4
+ Tc e l l s
With the assay optimized we set out to evaluate the cap-
acity of DRibbles to characterize CEF and particularly
CMV pp65 immunity across a population of donors. In
these studies monocytes loaded with CEF-DRibbles
stimulated more CD8 T cells than control E6E7-DRibbles
(2.4% vs 0.06%; p<0.01; Figure 2A) and CD4
+ T-cells
(0.56% vs 0.03%; p<0.05; Figure 2B). Stimulation with
E6E7-DRibbles did not increase the response beyond
the frequency observed in the no antigen groups. These
results showed that, when loaded onto monocytes, HEK
293 T derived DRibbles, cross-presented viral antigens
to both antigen-specific CD8
+ T cells and CD4
+ Tc e l l s
response. There was no apparent non-specific stimulation
of memory T cells by DRibbles derived from HEK 293 T
cells lacking the CEF antigenic peptides.
We also used DRibbles derived from the UbiLT3 cell
line, which was derived from a patient with NSCLC. A
line of UbiLT3 that expressed the pp65 protein of CMV
was generated and used to prepare DRibbles as a source
of CMV pp65 antigens to stimulate PBMCs from 24
donors. The percentage of IFN-γ
+CD8
+ T cells and IFN-
γ
+CD4
+ T cells were calculated following intracellular
staining protocol described above. The mean percentage
of IFN-γ
+CD8
+ T cells was 0.24% for the UbiLT3 pp65
DRibbles-stimulated group compared to 0.08% in the
paired group of T cells treated with control UbiLT3 GFP
DRibbles (p<0.01; Figure 2C,E). The mean percentage of
CD4
+ T-cells that produced IFN-γ upon pp65 DRibbles
stimulation was 0.54%, vs 0.04% following stimulation
with control DRibbles (p<0.01; Figure 2D,E). Compared
to purified recombinant CMV pp65 protein, UbiLT3 pp65
DRibbles were better stimulators of memory CD4
+ Tc e l l s
(0.54% vs 0.39%, p <0.05, Figure 2D,E) but less stimula-
tory to memory CD8
+ T cells (0.24% vs 0.58%, p < 0.01,
Figure 2C,E). These data show that DRibbles from
HEK293T cells and UbiLT3 cells are potent immuno-
gens for antigen-specific activation of CD8
+ T cells
and CD4
+ T cells when loaded onto elutriated mono-
cytes or added directly to human PBMCs.
Poly (I:C) enhances the cross-presentation of DRibble
antigens by PBMCs
We recently demonstrated that DRibbles express CLEC9A
ligand and were efficiently cross-presented by mouse
CLEC9A
+ DC [9]. In humans, CLEC9A expression is
restricted to the subset of BDCA3(CD141)
+ DC. Because
of its superior ability to cross present cell-associated
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is generally accepted that human BDCA3 (CD141)
+ DC
are the human counterpart of mouse CD8α
+ cDCs which
can efficiently capture dead or dying cells, process, and
cross-present exogenous antigens for the induction of
protective CD8
+ cytotoxic Tcell responses [15,16]. Several
studies have revealed that human CD141
+ mDCs express-
ing high levels of TLR3 could cross-present exogenous
antigens efficiently when the TLR3 agonist, poly (I:C),
was added to the assay [17,18]. Thus we tested whether
the addition of poly (I:C) to PBMCs with UbiLT3 pp65
DRibbles would further increase the percentage of pp65-
specific IFN-γ
+ T cells. Figure 3A shows that the addition
of poly (I:C) to DRibbles significantly enhanced the per-
centage of IFN-γ producing CD8
+ T cells as compared
to DRibbles without poly (I:C) (2.99% vs 0.10%, P<0. 05 ).
The combination of CD40L and Poly (I:C) did not further
increase the CD8
+ T cell response and CD40L alone
did not significantly increase the percentage of IFN-γ-
secreting CD8
+ T cells (Figure 3A). Neither the addition of
poly (I:C) nor CD40L affected the CD4
+ T cell responses
(1.96% vs 2.13%, P>0.05, Figure 3B). We found that under
these inflammatory conditions the pp65 specific CD8+ and
CD4+ T cell responses stimulated by DRibbles is still
dependent on antigen presenting cells (Additional file 1:
Figure S1).
The addition of other TLR agonists showed that Poly
(I:C), CpG, and LPS could enhance the cross-presentation
of UbiLT3 pp65 DRibbles, whereas R848 (TLR7/8 agonist)
and TLR2 agonist had no effect on the CD8
+ T-cell re-
sponse (Additional file 2: Figure S2A). The pp65 specific
CD4
+ T cell response was not affected by any of the TLR
agonist tested (Additional file 2: Figure S2B).
GM-CSF further enhances DRibble-induced CD8
+
T-cell responses
Martinuzzi and colleagues reported that GM-CSF/IL-4 and
maturation factors induced accelerated cocultured DCs
from unfractionated PBMCs and enhanced Ag-specific
T-cell stimulation [19]. Thus we investigated whether
the addition of GM-CSF/IL-4 would further enhance
the Ag-specific T-cell stimulation by DRibbles. PBMCs
were cultured in media supplemented with GM-CSF and
IL-4 for 12 hours; poly (I:C), CD40L and UbiLT3 pp65
DRibbles were added into the culture system, brefeldin
A was added and the percentage of IFN-γ
+ T cells was
measured by flow cytometry. The addition of GM-CSF
and IL-4 increased the percentage of Ag-specific CD8
+
AB
CD
Time before addition of Brefeldin A (hrs)  
Figure 1 The kinetics of CD4 and CD8 T-cell activation following exposure to DRibble-pulsed APC. (A,B) PBMCs were separated into
monocytes and lymphocytes by Elutra apheresis. Monocytes were pulsed with CEF DRibbles for 6 hours. After that time autologous T cells were added
into wells at a ratio of 5:1 (T cells:monocytes). Brefeldin A was added to the culture after the time periods specified in the figure. All cells were harvested
at the same time and prepared for flow cytometry. (C,D) PBMCs (monocytes and T cells) were cultured with pp65 DRibbles and then Brefeldin A was
added to the culture after the time periods specified in the figure. Cells were harvested at the same time and prepared for flow cytometry.
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(Figure 3C), but did not increase the Ag-specific CD4
+
T cell response (2.53% vs 2.41%, p >0.05, Figure 3C).
GM-CSF, but not IL-4, was required for the increase
in DRibbles stimulated pp65-specific responses; no sig-
nificant difference was found when IL-4 was omitted
from the culture (Additional file 3: Figure S3A,B). In
addition, we also tested type I interferon (IFN-α-2b),
type II interferon (IFN-γ), IL-1α,T N F - α,a n dt h e yd i d
not have a significant effect (Additional file 3: Figure
B
D
0.80% 0.30% 0.07% 0.02%
1.37% 1.95% 0.15% 0.01%
pp65 protein pp65 DRibbles GFP DRibbles No antigen
CD8
CD4
I
F
N
-
A
C
E
Figure 2 DRibbles were efficient antigen carriers for the activation of human CD8
+ T cells and CD4
+ T cells. PBMCs were separated
according to their density into monocytes and lymphocytes by Elutra apheresis. DRibbles were collected from HEK 293 T cells that expressed E6E7
protein or CEF protein. Monocytes were loaded with 25ug/ml CEF DRibbles or 25ug/ml control E6E7 DRibbles. After 6 hours, lymphocytes were added.
Activation of T cells was assessed by determining the percentage of IFN-γ
+CD8
+ cells (A) and IFN-γ
+CD4
+ cells (B) detected by ICS. The mean ± SEM of 3
separate experiments from the same donor are shown. CD8
+ (C) and CD4
+ T cell responses (D) against UbiLT3 pp65 DRibbles or control UbiLT3 GFP
DRibbles and CMV pp65 protein were analyzed in frozen-thawed PBMCs from 24 subjects. (E) shows the representative dot plot from one of the donors.
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ing experiments.
Proteasome inhibition positively affects the ability of
DRibbles to induce pp65-specific CD8
+ T cell response
We previously demonstrated that proteasome inhibition
resulted in accumulation of ubiquitinated proteins, which
were shunted into autophagosomes in mouse tumor
models and following vaccination improved cross-presen-
tation of short-lived proteins [5,9,11]. Here, we sought
to extend these observations to the human system. We
prepared lysates and DRibbles from untreated UbiLT3
cells or cells in which proteasome function was inhibited
by bortezomib treatment and performed western blots
with anti-ubiquitin and anti-pp65 antibodies (Figure 4A).
We found that ubiquitinated proteins were greatly
enriched in cell lysates after bortezomib treatment and
similar amounts of pp65 protein were found in lysates
and DRibbles regardless of bortezomib treatment. The
higher molecular weight bands recognized by anti-pp65
antibody in DRibbles likely represent accumulation of
ubiquitinated pp65 proteins in DRibbles following pro-
teasome inhibition.
The UbiLT3 pp65 cell line and control UbiLT3 cell
line were either untreated or treated with bortezomib
before DRibbles were isolated and added to PBMCs to
activate antigen-specific T cells under optimized condi-
tions. Our results showed that DRibbles isolated from
bortezomib-treated tumor cells induced more antigen-
specific CD8
+ T cells than DRibbles from untreated
tumor cells (Additional file 4: Figure S4). It is worth
noting that following proteasome inhibition stimulation
with DRibbles increased CD8
+ T cell responses, how-
ever, proteasome inhibition had no effect on stimulation
by cell lysates. Importantly, when compared at equivalent
doses, UbiLT3 pp65 DRibbles stimulated antigen-specific
CD8
+ T cells more effectively than UbiLT3 pp65 cell
lysates (P <0.05, Figure 4B). Surprisingly, DRibbles were
either equivalent (at low dose) or slightly less effective
(at high doses) than total cell lysates at stimulating
CD4
+ T-cell responses (P < 0.05, Figure 4C,D). Thus,
DRibbles as a pp65 antigen source has a greater ability
to cross-prime CD8
+ T cells than tumor lysates. The
increased CD8
+ T cell activation seemed to correlate
well with enrichment of ubiquitinated pp65 proteins in
DRibbles, but not lysates.
Figure 3 CD8
+ T cell response can be enhanced by adding Poly (I:C) and GM CSF/IL-4 to DRibble-pulsed PBMCs. Poly (I:C) and CD40L
were added with UbiLT3 pp65 DRibbles (25ug/ml) to rested PBMCs. The mean ± SEM of 3 separate experiments are shown. (A) represents the
percentage of IFN-γ producing CD8
+ T cell and (B) represents the CD4
+ T cell response. (C) PBMCs were cultured with or without GM-CSF and
IL-4 for 12 hours, then Poly (I:C) and CD40L were added to PBMCs with UbiLT3 pp65 DRibbles (25ug/ml). The mean ± SEM of 3 separate experiments
are shown.
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In contrast to the recent clinical success of adoptive T-
cell immunotherapy and antibodies that interfere with
T cell checkpoints, which prove the therapeutic value
of T cells, active-specific immunotherapy with cancer
vaccines has been disappointing and much less effective.
Many reasons, including poor immunogenicity, immune
evasion and immune suppression could explain this failure
[20]. Approaches to induce a robust antigen-specific
CTL response against multiple cancer-associated anti-
gens, which appears to be required for the clearance of
tumor cells by the immune system has become a major
focus for the development of therapeutic cancer vaccines.
CTL recognition of tumor cells, or normal cells infected
with viruses, is via peptides, that are presented by MHC I
complexes. The dominant peptides contained in MHC I
on the cell surface are thought to be derived from short-
lived proteins or defective ribosomal products (DRiPs)
[9,10]. To increase the cross-priming of tumor-specific
CTL, we developed a novel vaccine based on tumor-
derived autophagosomes (DRibbles), in which short-lived
proteins and DRiPs could be highly enriched after prote-
asome and lysosome function were inhibited. DRibbles
induce efficient cross-presentation, activate naïve CD8
+
Tc e l l sin vivo and in vitro, and induce cross-protective
and therapeutic antitumor immune responses against
multiple, antigen distinctive, sarcomas [11] and mammary
carcinomas (Twitty C et all manuscript in preparation,
L iYe ta lm a n u s c r i p ti np r e p a r a t i o n ) .
In this study, we sought to determine whether DRibbles
could be used to cross-present viral antigens to human
T cells. We showed that DRibbles derived from either
the HEK293T cell line or UbiLT3 cell line expressing
the CMV pp65 antigen accumulated both native and
Figure 4 Antigen-specific CD8
+ and CD4
+ T cells response following stimulation by DRibbles or cell lysates. (A) The ubiquitinated proteins
and pp65 proteins contained in the cell lysate and DRibbles were examined by western blot. Lysates and DRibbles extracted from cell lines treated
with bortezomib contained more ubiquitinated proteins than those from non-treated cells (left). The pp65 protein was detected in the lysates and
DRibbles extracted from the UbiLT3 pp65 cell line. The pp65 DRibbles collected from the bortezomib-treated UbiLT3 pp65 cell line contained more
148Kd pp65 protein compared with the other groups (right). Data are representative of 3 independent experiments. (B,C) PBMCs were stimulated
by DRibbles and cell lysates at the following doses: 3ug/ml, 10ug/ml and 25ug/ml. The percentage of IFN-γ
+CD8
+ (B) and IFN-γ
+CD4
+ cells
(C) were calculated by flow cytometry. Percentages of IFN-γ
+ T cells are shown as mean ± SEM. Data are representative of results from 3
independent experiments. (D) Dot plots at the antigen dose of 25ug/ml.
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specific human CD4
+ and CD8
+ T cells when loaded
onto monocytes or directly to unfractionated PBMCs
in vitro. For the optimal activation of antigen-specific T
cell responses in PBMCs, it requires at least 10 hours
of processing and presentation of DRibbles by APCs.
Moreover, we found that cross-presentation efficiency
was significantly enhanced by adding GM-CSF+IL-4,
CD40L, and the TLR3 agonist (poly(I:C)) to the culture
with DRibbles.
In this study, we used artificial CEF and CMV pp65 as
model antigens to investigate whether they could be cross-
presented and stimulate T cell responses from pre-existing
human memory Tcells. CEF is a synthetic antigen compris-
ing 32 MHC class I restricted epitopes from CMV, EB and
influenza virus, which are recognized by human donor viral
antigen-specific CD8
+ T cells [14]. Initially, we loaded
conventional monocyte-derived DCs with CEF-DRibbles
to activate T cell responses, but found that freshly isolated
monocytes could also cross-present DRibble antigens to
CD8
+ T cells very efficiently without ex vivo culture. The
monocytes were isolated from PBMCs by elutriation, but
it is very likely that blood DCs were also present and
participated in the cross-presentation of antigens from
DRibbles. Recently, it has been reported that the CLEC9A
+
BDCA3
+ DC subset in human PBMCs and tissues can
efficiently cross-present cell death-associated antigens
[15,21,22]. We can only speculate that the efficient
cross-presentation of DRibble antigens was mediated
by these DCs, a notion that is being investigated in the
lab currently (Hilton, manuscript in preparation; van de
Ven, manuscript in preparation).
Based on these initial results, we added DRibbles directly
to PBMCs to investigate their ability to activate pre-existing
memory CD8
+ and CD4
+ T cells response without prior
APC isolation and antigen loading. We chose DRibbles
derived from the UbiLT3 and HEK293T cell lines that
expressed the CMV pp65 antigen, because pp65 is a
dominant antigen recognized by both memory CD8
+ and
CD4
+ T cells in humans with a history of CMV infection
[12]. In addition to their ability to stimulate CD8
+ Tc e l l s,
DRibbles efficiently induced CMV-specific human CD4
+
T cells with a similar or slightly higher efficiency than
purified pp65 protein. Thus DRibbles can also be pre-
sented and cross-presented by APCs in humans and
stimulate both CD4 and CD8 Tcells, respectively.
In this study, intracellular IFN-γ production was the
surrogate measure for effective cross-presentation. The
process from cross-presentation of DRibbles by APCs
to IFN-γ production by memory T cells is lengthy and
complex one; it comprises DRibbles uptake, protein
degradation, peptide transport and loading, and finally
presentation to T cells. Thus, it is not surprising that it
took more than 10 hours for DRibbles to induce efficient
CD8
+ and CD4
+ T cell responses, whereas it only takes
2-6 hours for peptide antigen pulsed APCs to stimulate
IFN-γ production [23]. This information will allow the
further optimization of assays for monitoring T cell re-
sponses of patients on clinical trials.
Three subsets of human peripheral blood DCs have
been described: pDCs; BDCA1
+ cDCs; BDCA3
+CELC9A
+
cDCs [24]. Efficient cross-presentation generally requires
DC activation signals. These signals are often triggered by
engagement of their TLRs [13]. Prior reports have shown
that APCs respond to TLR ligands in accordance with
their TLR expression pattern. When pDCs, which express
TLR7 and TLR9, are stimulated with either CpG or R848,
they exhibit a dramatic and rapid up-regulation of the
co-stimulatory molecules CD40, CD80, CD86, CD83, as
well as MHC class II molecules, and production of IFN-α
[13,25,26]. BDCA1
+ DCs express a broad spectrum of
TLRs, and can respond to poly (I:C), LPS, and R848 [27].
BDCA3
+CLEC9A
+ cDCs, a newly described DC subset
that expresses XCR1 and TLR3, have the highest capacity
to cross present cell-associated antigens [28]. This DC
subset is analogous to the mouse CD8α
+ DCs. Consistent
with their high level of TLR3 expression, studies have
shown that stimulation with poly (I:C) leads to secretion
of large amounts of IL-12 p70, IFN-γ, and most import-
antly enhanced ability to cross present antigen [22,27].
We recently showed that DRibbles were recognized
by CLEC9A and that cross-presentation of DRibbles by
mouse DCs was decreased if DRibbles were preincubated
with soluble CLEC9A protein as a decoy receptor [9].
Thus, we posit that DRibbles can be most efficiently
cross-presented by human blood BDCA3
+CLEC9A
+ DCs.
Our preliminary cell sorting studies also support this
notion. We investigated the effect of different TLR ago-
nists on the cross-presentation ability of PBMCs. Our data
showed that poly (I:C), CpG, and LPS can enhance the
cross presentation of DRibbles, particularly poly (I:C).
The CD8
+ T cell response to DRibbles appeared to be
enhanced when recombinant CD40L was added to the
culture. These observations are consistent with recent
publications showing that optimal cross-presentation by
blood BDCA3
+CLEC9A
+ DCs requires TLR3 signaling
and a licensing factor, such as CD40L [18,19].
Martinuzzi E et al, found that accelerated cocultured
DC (acDC), produced by culturing PBMCs with GM-CSF
and IL-4 for 24 h and then adding maturation stimuli for
an extra 24 h, could enhance the expansion of antigen-
specific T cells and that acDC-amplified T-cell responses
were antigen specific [19]. Similarly, we showed that
PBMCs could efficiently stimulate T-cell responses when
they were cultured with GM-CSF plus IL-4 for 12 h,
followed by DRibbles and Poly (I:C)/CD40L for an extra
24 h. However, minor differences in the effect of cytokines
were observed. For example, adding IL-4 was not needed
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not have a significant effect. In addition, the cross-
presentation of DRibbles can be decreased dramatically
when exogenous IFN-α was added to the culture together
with DRibbles. Thus, for efficient cross-presentation of
DRibbles, only GM-CSF is needed and sufficient for the
rapid functional differentiation of blood DCs when in
the presence of DRibbles. DRibbles contain many endogen-
ous agonists for multiple TLRs expressed by monocytes
and DCs, which could induce rapid differentiation of
monocytes or other DC precursors in human blood when
combined with GM-CSF. After that we compared the
ability of poly (I:C) plus different cytokines to enhance
CD8
+ T cells response in the background of GM-CSF.
We conclude that GM-CSF can sustain the survival and
function of APCs during both recovery of PBMCs from
cryopreservation and antigen loading and presentation,
while adding poly (I:C) plus CD40L at the same time of
antigen loading appeared to be the optimal condition
that should be adopted. The negative effect of adding
exogenous IFN-α on the cross presentation of DRibbles
needs further investigation. IFN-α was shown to be the
critical cytokine for cross-priming of antitumor immune
response in mice [29,30]. However, adding IFN-α to
monocytes together with GM-CSF for three days of
culture prior to DRibbles loading was found to be benefi-
cial for functional differentiation of DCs, consistent with
published work showing that blood monocyte can be
induced to differentiate into DCs stimulated by GM-
CSF plus IFN-α [31].
The CMV pp65, nonessential protein for virus replica-
tion, is the most abundant tegument protein and major
constituent of extracellular viruses. Although, it is not
known as a short-lived protein, treatment of pp65 express-
ing cells with proteasome inhibitor enhanced its cross
presentation efficiency when either whole cell or DRibbles
were used to induce the activation of antigen specific
CD8
+ T cells. However, proteasome inhibitor treatment
did not have any effect when cell lysate antigen was
used. Furthermore, proteasome inhibition seems to have
much less effect on CD4
+ T cell responses to DRibbles
or cell lysates. We speculate that stable long-lived pp65
proteins are major antigens that are presented to CD4
+
T cells, whereas ubiquitinated pp65 proteins are major
antigens presented to CD8
+ T cells as it appeared that
more ubiquitinated pp65 proteins can be enriched in
bortezomib treated DRibbles and levels of ubiquitinated
pp65 rather than levels of natively folded pp65 correlated
with increased CD8
+ T cells activation after proteasome
inhibition. In murine models, we showed that the cross-
presentation of short-lived antigens can be enhanced by
inducing cell autophagy with a proteasome inhibitor and
blocking p62-dependent accumulation of DRiPs in DRib-
bles diminished the cross-presentation [5].
Inactivated whole tumor cells or tumor cell lysates are
commonly used in traditional vaccine strategy for cancer
immunotherapy [32]. One major advantage of our novel
DRibbles vaccine is the enrichment of short-lived pro-
teins or ubiquitinated DRiPs of misfolded proteins. The
majority of these SLiPs and DRiPs are not expected to
be contained in vaccines of inactivated whole tumor cells
or tumor cell lysates due to rapid degradation. Thus,
whole cell or cell lysate vaccines will not efficiently cross-
present these tumor/tumor-associated antigens derived
from SLiPs and DRiPs. Because SLiPs and DRiPs are not
normally cross-presented tumor-bearing hosts are unlikely
to be tolerant to these antigens. Thus, tumor-associated
antigens contained in SLiPs and DRiPs represent a reper-
toire of neo-antigens against which the host should be
able to generate a strong immune response [6]. Our
current work suggests that combinations with other
adjuvants may increase the immune response directed
against the DRibble vaccine. The ongoing multicenter
phase II clinical trial will evaluate the ability of two
adjuvants, GM-CSF and imiquimod, to further augment
immune responses against tumor-associated antigens.
Conclusions
Our study highlights the ability of DRibbles to activate
memory antigen-specific CD8
+ and CD4
+ T cells in human
peripheral blood. The results demonstrate that DRibbles
can efficiently cross-present antigens to human memory T
cells. Coupled with our experience in preclinical cancer
models, these data suggest that DRibbles may be an excel-
lent vehicle for priming and boosting anti-cancer immune
responses in patients as well as for monitoring anti-cancer
immune responses. We are currently testing this strategy in
a multicenter randomized phase II clinical trial for patients
with definitively treated stage IIIA/B non-small cell lung
cancer.
Additional files
Additional file 1: Figure S1. pp65 specific CD8
+ and CD4
+ Tc e l l s
response stimulated by DRibbles is dependent on antigen presenting cells.
(A) Pure T cells were sorted from human PBMC using Macs Pan T cell
isolation kit from Miltenyi Biotec. Then Poly (I:C) and CD40L were added
with UbiLT3 pp65 DRibbles or negative control UbiLT3 GFP DRibbles
(25ug/ml) to rested PBMC or pure T cells. ICS analysis was done as before.
(B) represents CD8
+ T cells response. (C) represents CD4
+ T cells response.
Additional file 2: Figure S2. CD8
+ and CD4
+ T cell responses after
stimulated by different TLR agonists. Different agonists were added into
PBMCs along with UbiLT3 pp65 DRibbles. (A) CD8
+ T cell response.
(B) CD4
+ T cell response.
Additional file 3: Figure S3. Compare the abilities of GM-CSF/IL4 and
Poly (I:C) to enhance T cells response with other cytokines. PBMCs were
cultured with cytokines for 12 hours, then HEK 293 pp65 Dribbles were added
along with Poly (I:C) or Poly (I:C) and CD40L. (A,B) shows the data that
compares GM-CSF + IL-4 with GM-CSF only with or without Poly (I:C)+
CD40L. (C,D) shows the data comparing GM-CSF + IL-4 with GM-CSF +
IFN-α-2b, IFN-α-2b and GM-CSF + IL-4+IFN-α-2b. (E,F) DRibbles were
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protein. PBMCs were loaded with 25ug/ml HEK 293 T pp65 DRibbles or
control HEK 293 T OVA DRibbles. At the same time, Poly (I:C) was added
into the system with or without other cytokines. Then ICS analysis was
done as before.
Additional file 4: Figure S4. Treatment with bortezomib enhances the
abilities of cells and DRibbles to stimulate Ag-specific CD8
+ T-cell. The
UbiLT3 pp65 cell line was cultured with or without bortezomib for 48 hours.
DRibbles, cell lysates and whole cells were prepared from bortezomib
treated and untreated groups and added to PBMCs as a stimulator. (A,B)
shows the CD8
+ T cell response in donor #1 and #2. (C,D) shows the
CD4
+ T cell response in donor #1 and #2.
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